Tests for candidiasis

PreclinicalBiologic

CCentre Hospitalier Universitaire de Nīmes

Tests for candidiasis is one of 30 biologic programs targeting Candidiasis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CandidiasisActive, not recruiting

CandidiasisPreclinical

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Candidiasis

#DrugCompanyPhaseTrials

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

17 2

Mycamine

BBaxter Healthcare Corporation

Approved

12 3

Cancidas

FFresenius Kabi Oncology Ltd.

Approved

8 4

Eraxis

VVicuron Pharmaceuticals

Approved

4 5

Sporanox

SSebela Pharmaceuticals Development LLC

Approved

2 6

Vfend

PPrism Pharmaceuticals

Approved

2 7

Lotrimin

Bayer

Phase 3

1 8

Ambisome

Gilead

Approved

1 9

Mycostatin

GGood Molecules, LLC

Phase 3

2 10

Nizoral

WWim Janssens

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Candidiasis1 trial

Staging Candidiasis in ICU Patients

Completed·—··NCT01322698·422 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tests for candidiasis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tests for candidiasis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tests for candidiasis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Hospitalier Universitaire de Nīmes company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: CCentre Hospitalier Universitaire de Nīmes

Tests for candidiasis

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Candidiasis1 trial

References

Drug Info

Quick Facts

Related News